cncpt-artikel_lb_atf
Clinical benefit of nivolumab plus cabozantinib 1st line advanced renal cell carcinoma across subgroups
The CheckMate 9ER study shows an improved PFS across all subgroups. The combination was approved by EMA in March 2021.